NICE process and methods

1 Decision problem, description of the technology and clinical care pathway

1 Decision problem, description of the technology and clinical care pathway

1.1 Decision problem

Please choose the most appropriate option(s) from those provided in the submission template about whether the submission covers all or only part of the technology's marketing authorisation for this indication.

Specify the decision problem that the submission addresses. Present the decision problem in the table in section 1.1 of the template, making reference to the final NICE scope.

1.2 Description of technology being evaluated

Provide details of the technology being evaluated using the table in section 1.2 of the template.

1.3 Health condition and position of the technology in the treatment pathway

1.3.1

Provide a brief overview of the disease or condition for which the technology is indicated.

1.3.2

Present the clinical pathway of care that shows the context of the proposed use of the technology. This information should be summarised in a diagram if possible. Explain how the new technology may change the existing pathway. Include details of any subsequent treatments that are used in current clinical practice and how these are expected to change if the new technology was to be introduced. If a relevant NICE clinical guideline has been published, the response to this point should be consistent with the guideline and any differences should be explained.

1.4 Equality considerations

1.4.1

NICE is committed to promoting equality of opportunity, eliminating unlawful discrimination and fostering good relations between people with particular protected characteristics and others. For further information about equality issues see NICE's equality action plan.

1.4.2

Provide an assessment of whether the use of this technology is likely to raise any equality issues. Please document any potential issues that:

  • could exclude from full consideration any people protected by the equality legislation who fall within the patient population for whom the technology is or will be licensed

  • could lead to recommendations that have a different impact on people protected by the equality legislation compared with the wider population, for example, by making it more difficult in practice for a specific group to access the technology

  • could lead to recommendations that have any adverse impact on people with a particular disability or disabilities.

1.4.3

Please provide any evidence that would enable the committee to identify and consider the impact of equality issues. State how the analysis has addressed these issues.